Brozaar (Losartan potassium) is generally used for the long-term management of chronic conditions to help support functional stability. The medication is considered relevant across therapeutic domains involving chronic vascular and renal strain.

---

The primary therapeutic domain is the management of high blood pressure (hypertension) in adults and children aged 6 years and older. It helps address symptoms related to systemic imbalance in conditions characterized by increased physiological stress. The therapy may assist with reducing the likelihood of major long-term cardiovascular events, such as a stroke or heart attack.

A secondary therapeutic area is relevant for diabetic kidney disease (nephropathy) in patients with Type 2 diabetes, and for managing heart failure. This makes its use relevant across conditions presenting with systemic or localized discomfort affecting multiple organ systems.

“The therapy contributes to easing the overall symptom load, which supports general well-being during symptomatic phases.”

Quick Fact: Relief for Symptoms that Interfere with Daily Functioning

This specialized use is applied in clinical settings to ease symptoms that create noticeable physiological strain in heart failure and to address organ-specific functional stress in kidney disease. It contributes to supporting the management of progressive conditions and may help patients cope more steadily with symptom fluctuations.

Regulatory References

1. NIH DailyMed official Losartan labeling

Who can and cannot use Brozaar?

Brozaar (Losartan potassium) use is strictly governed by official regulatory eligibility rules that define permitted and excluded populations.

Absolute Non-Eligibility (Contraindications)

The medicine is contraindicated and must not be used by patients with a known hypersensitivity to losartan or any component of the tablet. Use is strictly prohibited during the second and third trimesters of pregnancy due to the risk of fetal toxicity; discontinuation is mandatory upon detection of pregnancy. It is also contraindicated in patients with severe hepatic impairment and in patients with diabetes or certain renal impairments who are concomitantly taking Aliskiren.

Age and Use Restrictions

Brozaar is approved for adults for all uses, but use in children is limited. It is approved only for pediatric patients 6 years and older for hypertension and is not recommended for children under this age or those with severe kidney function issues (GFR < 30 mL/min/1.73 m²). Use is not recommended while breastfeeding. Patients with mild-to-moderate hepatic impairment or those who are volume-depleted may require conditional use as per labeling.

Interactions with other medicines and products

Brozaar (Losartan potassium) interacts with several medicinal product categories, as documented in official regulatory sources. These interactions are primarily classified as pharmacodynamic (additive physiological effects) or pharmacokinetic (altered drug concentration profiles).

Interaction Classification	Interacting Agents (Examples)	Official Outcome
Contraindicated	Aliskiren	Prohibited in patients with diabetes mellitus or moderate-to-severe renal impairment due to increased risk of hyperkalemia and renal function decline.
Pharmacodynamic Risk	Potassium-sparing diuretics, Potassium supplements, NSAIDs	Increased risk of hyperkalemia with potassium-retaining agents. NSAIDs are documented to reduce the blood pressure-lowering effect and increase the risk of acute renal function changes.
Pharmacokinetic	Fluconazole (CYP2C9 inhibitor), Rifampin (CYP inducer)	Fluconazole significantly increases the overall plasma exposure ( AUC) of Losartan and decreases the exposure of its active metabolite. Rifampin is documented to decrease the AUC of both the parent drug and its active metabolite.
Altered Clearance	Lithium preparations	Causes a documented, reversible increase in serum lithium concentrations due to reduced renal clearance, increasing the risk of toxicity.

The official interaction profile is structured around two core concerns: additive pharmacodynamic risk, particularly concerning potassium balance and renal function, and pharmacokinetic modulation via the CYP2C9 enzyme pathway. While administration with food has only a minor impact on Losartan's overall exposure, regulatory labels note that in patients with hepatic impairment, Losartan exposure is significantly increased, which affects its interaction potential.

Targeting the Signals for Vascular Growth

Brozaar works by precisely targeting the Vascular Endothelial Growth Factor Receptors (VEGFR-1, -2, and -3) on the surface of cells. It acts as a tyrosine kinase inhibitor, a mechanism that directly blocks the ability of these receptors to become activated and transmit internal signals that drive cellular multiplication and expansion into the cell's core pathways, such as PI3K/Akt and RAS/RAF. This targeted action is fundamental to modulating overactive signaling associated with heightened activity in the targeted pathways.

---

Modulating the Formation of New Vessels

A core physiological consequence of blocking the VEGFR pathways is the inhibition of angiogenesis (new blood vessel formation) and lymphangiogenesis (new lymphatic vessel formation). By restricting the growth of the necessary vascular infrastructure, Brozaar reduces the supply of blood, oxygen, and nutrients to targeted cells. This mechanistic effect contributes to the resulting physiological adjustment of restrained cellular expansion, resulting in the modulation of dysregulated growth signaling.

Brozaar (losartan potassium) is an Angiotensin II Receptor Blocker (ARB) prescribed for the treatment of hypertension (high blood pressure) and to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy. It is also used to manage diabetic nephropathy in patients with type 2 diabetes and a history of hypertension.

Administration Guidelines

• Dosage: Brozaar is typically taken once daily, with the exact milligram (mg) dosage determined by a healthcare provider based on the treated condition and individual response. For most adults with hypertension, the usual starting dose is 50 mg once daily, with a maximum dose of 100 mg once daily. Patients with intravascular volume depletion (e.g., those on high-dose diuretics) may begin with a lower dose of 25 mg once daily.
• Timing: The tablet can be taken with or without food. It should be swallowed whole with water. Consistent daily timing is advised to maintain stable blood pressure control, regardless of whether it is taken in the morning or evening.
• Missed Dose: If a dose is missed, take it as soon as you remember. If it is close to the time for your next scheduled dose, skip the missed dose and resume your regular dosing schedule. Do not take a double dose to compensate for the missed one.

Important Precautions

Brozaar is intended for long-term use and must be continued as directed by your physician, even when blood pressure is controlled. Suddenly stopping the medication can cause blood pressure to rise. Regular monitoring of blood pressure, kidney function, and serum potassium levels is necessary during therapy.

Research Evidence / Overview of Studies for Brozaar

Evidence for Use in Managing High Blood Pressure (Hypertension)

Research examining Losartan potassium for high blood pressure includes Randomized Controlled Trials (RCTs) and large-scale analyses. These studies compared the substance against a placebo or other active medications. The studies monitored outcomes related to systemic or functional imbalance, such as short-term and long-term readings of blood pressure, and also outcomes describing episodic or acute changes, such as the occurrence of major cardiovascular events.

The research describes the patterns measured in blood pressure readings in the observed populations during the study period. Long-term observation data describe patterns related to the frequency of serious events like stroke and cardiovascular death. However, studies also report that the observed changes in BP readings may be less prominent in certain patient groups, such as African American patients.

Research on Kidney and Stroke Outcomes

Research has explored the use of Losartan potassium in two specialized areas: research related to stroke events in a specific cardiac population and outcomes explored in managing certain aspects of kidney disease in people with diabetes.

Evidence for Diabetic Kidney Disease

Long-term trials focused on adults with Type 2 diabetes who also had hypertension and evidence of diabetic nephropathy (kidney disease). These studies monitored outcomes monitoring physiological strain or stress on the kidneys, including the rate at which kidney function readings changed and the need for dialysis. Findings from these dedicated renal trials described patterns related to the monitored progression of renal function when compared to the control group.

Research into Stroke Risk Reduction

Research exploring stroke risk was evaluated in a specific subgroup of hypertensive patients who also had a condition known as Left Ventricular Hypertrophy (LVH). The resulting findings describe patterns related to the incidence of stroke in this specific group. The monitored pattern of stroke events was not found in all subgroups, such as Black patients who participated, suggesting the findings may not apply universally.

Key Limitations and Areas of Research Uncertainty

Data for certain groups remain insufficient, particularly for extended-duration outcomes in children and for its comparative performance against certain other therapies. The existing studies provide context but not individual predictions about how any single person will respond.

Key Studies & References

1. Losartan: NIH DailyMed Official Labeling (US)

Common questions about Brozaar (FAQ)

Q: How long does Brozaar stay in my system?

A: According to pharmacokinetic data in the official product information, the component of Brozaar that is active in the body has an estimated terminal half-life typically ranging from 6 to 9 hours. This time frame describes how long it takes for half of the active substance to be eliminated from the bloodstream.

Q: Can I stop taking Brozaar abruptly?

A: Suddenly stopping this medication is associated with the risk of blood pressure rising rapidly. Because of this potential effect, a decision to stop or change treatment requires consultation with a healthcare provider.

Q: What should I do if the side effects from Brozaar bother me?

A: Official guidance recommends consulting a healthcare provider if any side effects become severe, persistent, or do not go away. This is for professional assessment and review of the treatment plan.

Q: What is the main difference between Brozaar and other similar medicines?

A: Brozaar is officially classified as an Angiotensin II Receptor Blocker (ARB). This class of medicine works by blocking the effects of the hormone Angiotensin II on its specific receptor sites to regulate blood pressure. This mechanism differs from other medicine classes, such as beta-blockers or ACE inhibitors, which operate differently.

Q: Does Brozaar thin your blood?

A: Brozaar is classified as an Angiotensin II Receptor Blocker (ARB) used primarily for blood pressure regulation and managing certain heart and kidney conditions. It is not an anticoagulant and does not function as a blood thinner.

Q: Can Brozaar cause weight gain?

A: Weight gain was not reported as an adverse reaction in the clinical trials reviewed for official regulatory labeling. However, edema (swelling) is documented as a less common side effect, which can sometimes be associated with temporary fluid-related weight changes.

Q: Does Brozaar help with anxiety or stress?

A: The approved uses for Brozaar are focused on managing hypertension (high blood pressure) and specific kidney conditions in diabetic patients. The drug's regulatory label does not list treatment for anxiety or stress as an approved indication.

Q: How quickly does Brozaar start working?

A: Pharmacokinetic data shows that Brozaar is rapidly absorbed after ingestion. It typically reaches its maximum concentration in the bloodstream within 1 to 2 hours after being taken.

Q: Can Brozaar affect sleep?

A: Official documentation lists Insomnia (difficulty sleeping) as a common side effect of the medicine. Other general sleep disorders are also listed, though they occur less frequently.

Q: Are there any foods or drinks to avoid while taking Brozaar?

A: Regulatory safety information indicates that potassium-containing salt substitutes should be avoided, as taking them with Brozaar can increase blood potassium levels. Certain patient information sources also advise caution regarding grapefruit juice and note that alcohol may increase the blood pressure-lowering effect.

Q: Does Brozaar cause liver problems?

A: The medication is contraindicated (must not be used) in patients who have severe hepatic impairment (severe liver dysfunction). Official labeling also documents Hepatitis as a rare adverse reaction.

Q: Is Brozaar a diuretic or a water pill?

A: Brozaar is officially classified as an Angiotensin II Receptor Blocker (ARB). It belongs to a separate pharmacological class and is not classified as a diuretic, commonly known as a water pill.

Q: Can Brozaar be used to treat migraines?

A: The approved regulatory indications for the drug are strictly the treatment of hypertension, the reduction of stroke risk in specific patient groups, and the management of diabetic nephropathy. Migraine treatment is not an officially approved use.

Q: Does Brozaar affect cholesterol levels?

A: Clinical studies have examined the drug's effects on cellular mechanisms related to small, dense LDL cholesterol particles. However, official regulatory agencies have not indicated the medication as a formal treatment for high cholesterol.

Q: Is it possible to develop a tolerance to Brozaar over time?

A: Clinical trials conducted on the medication have not reported the development of tolerance to the drug's intended blood pressure-lowering effect over time.

Q: What are the most common reasons someone would stop taking Brozaar?

A: In clinical studies, the overall rate of discontinuation due to adverse clinical experiences was reported to be low, specifically 2.3% in monotherapy trials. Discontinuation is typically based on a professional assessment of adverse clinical experiences.

Q: Can Brozaar affect male fertility?

A: Official patient information indicates there is no current evidence suggesting that taking Brozaar reduces fertility in men or women. However, it is strictly contraindicated during the second and third trimesters of pregnancy due to fetal risk.

Q: Is there any research on Brozaar's use in children?

A: The medicine is approved for the treatment of hypertension in children 6 years and older. Official clinical trial registries contain data on studies conducted to evaluate the drug's safety and effectiveness in pediatric patients.

Q: Does Brozaar interact with herbal supplements?

A: Official safety guidance advises that there is not enough data available to confirm the safety of taking most herbal remedies and supplements with Brozaar. This is because most herbal products are not tested for drug-drug interactions in the same way as prescription medicines.

Q: Is Brozaar a statin or related to them?

A: Brozaar is classified as an Angiotensin II Receptor Blocker (ARB). It belongs to a different drug class than statins (HMG-CoA reductase inhibitors), which are specifically used to lower cholesterol levels.

Q: What are the major contraindications listed for Brozaar?

A: Major contraindications (reasons the drug must not be used) include use during the second and third trimesters of pregnancy, known hypersensitivity to the drug, severe hepatic impairment, and concurrent use with Aliskiren in patients with diabetes or certain renal impairments.

Q: Can Brozaar cause changes in mood or confusion?

A: Official labeling lists psychiatric effects, including confusion, depression, and anxiety, as documented adverse reactions. However, their specific frequency is generally not reported as Common or Uncommon in clinical trials.

Q: Are there any listed restrictions on driving while taking Brozaar?

A: Regulatory labels advise that common side effects, such as dizziness or feeling lightheaded, may occur, especially when initiating therapy. These effects could impair the ability to perform tasks requiring attention, like driving or operating machinery.

Q: How is Brozaar's purpose officially described in regulatory documents?

A: Its purpose is officially described as the treatment of hypertension (high blood pressure), to reduce the risk of stroke in specific high-risk patients, and to manage diabetic nephropathy in patients with type 2 diabetes and hypertension.

Q: What if I vomit shortly after taking Brozaar?

A: Official regulatory documents do not provide specific instructions for vomiting shortly after a dose. The medication is rapidly absorbed; however, procedural guidance for such events typically requires consulting a healthcare provider.

Q: What is the relationship between Brozaar and potassium levels?

A: The medication can cause increased serum potassium levels, a condition known as hyperkalemia. Due to this risk, concomitant use with other potassium-retaining agents is a documented safety concern, and periodic monitoring of serum potassium levels is common during treatment.

Q: How is Brozaar eliminated from the body?

A: After being metabolized by the liver, the drug is eliminated from the body through two primary pathways: the urine (renal excretion) and the feces (biliary excretion).

Q: How does the action of Brozaar compare to a beta-blocker?

A: Brozaar is an ARB that works by blocking the effects of the hormone Angiotensin II, which relaxes blood vessels. A beta-blocker, by contrast, works by blocking the effects of adrenaline on the heart, causing it to beat slower and with less force.

Q: Does Brozaar require any special storage conditions?

A: Regulatory labels state that the tablets must be stored at controlled room temperature (20 C to 25 C). They must be kept in their original, tightly closed container and protected from both light and moisture.

Q: Can Brozaar interact with common cold or flu medications?

A: The official interaction profile documents risks with NSAIDs (Non-Steroidal Anti-Inflammatory Drugs), which are common active ingredients in many cold and flu medicines. This interaction can potentially reduce the blood pressure-lowering effect and affect kidney function.

Q: Is Brozaar safe to take long-term?

A: Brozaar is indicated for chronic conditions and is formally intended for long-term use for its approved indications. Continuous administration and regular health monitoring are typically part of the treatment plan.

Q: What kind of studies support the use of Brozaar?

A: Official documents cite support from Randomized Controlled Trials (RCTs) and long-term analyses. These studies monitor patient outcomes related to systemic blood pressure, the incidence of stroke, and the progression of diabetic kidney disease.

Brozaar (losartan potassium) tablets must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F). The medication must be kept in its original, tightly closed container and should be protected from light and moisture. Do not store the tablets in damp areas like a bathroom.

Special Storage and Stability

If the medicine is prepared as an oral suspension, it must be refrigerated (2 C to 8 C) and must not be frozen. Any unused suspension must be discarded after 4 weeks.

Child Safety and Disposal

All tablets must be stored out of the sight and reach of children. Unused or expired Brozaar must be disposed of in accordance with local requirements. The preferred method is a drug take-back option; otherwise, follow official guidance for safe disposal in household trash.